Difference between revisions of "Part:BBa K3132005"

(→‎MIT MAHE 2020)
Line 22: Line 22:
  
 
HER2 is a membrane tyrosine kinase and an oncogene. Studies have shown it to be overexpressed and gene amplified in about 20% of the breast cancers. On activation it provides the cell with potent proliferative and anti-apoptosis signals. It is one of the major driver of tumor development and progression for a subset of breast cancer. This part contains Anti-HER2 single chain variable fragment.
 
HER2 is a membrane tyrosine kinase and an oncogene. Studies have shown it to be overexpressed and gene amplified in about 20% of the breast cancers. On activation it provides the cell with potent proliferative and anti-apoptosis signals. It is one of the major driver of tumor development and progression for a subset of breast cancer. This part contains Anti-HER2 single chain variable fragment.
 +
 +
==NUM_China 2021==
 +
=== A scFv derevied from Hercetin===
 +
 +
This parts codes a scFv derevied from the famous antibody trastuzumab,which sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is given by slow injection into a vein and injection just under the skin.
 +
 +
Trastuzumab was approved for medical use in the United States in September 1998, and in the European Union in August 2000.It is on the World Health Organization's List of Essential Medicines.A biosimilar was approved in the European Union in November 2017, and in the United States in December 2018.
 +
 +
<div><ul>
 +
<center>
 +
  <li style="display: inline-block;"> [[File:T--NMU_China--TTZ.png|thumb|none|400px|<b>Figure 1:</b> Trastuzumab Fab region (cyan) binding HER2/neu (gold) available in PDB.]] </li>
 +
</center>
 +
    </ul></div>
 +
  
 
==References==
 
==References==
  
 
1. Gutierrez, C., & Schiff, R. (2011). HER2: biology, detection, and clinical implications. Archives of pathology & laboratory medicine, 135(1), 55–62. https://doi.org/10.1043/2010-0454-RAR.1
 
1. Gutierrez, C., & Schiff, R. (2011). HER2: biology, detection, and clinical implications. Archives of pathology & laboratory medicine, 135(1), 55–62. https://doi.org/10.1043/2010-0454-RAR.1

Revision as of 03:26, 2 October 2021


anti-HER2 scFV

Human epidermal growth factor receptors (HERs or ErbBs) play crucial roles in numerous cellular processes. ErbB2 is a key member of ErbB family, and its overexpression is recognized as a frequent molecular abnormality. In cancer, this overexpression correlates with aggressive disease and poor patient outcomes. Dimer-dependent phosphorylation is a key event for the signal transduction of ErbBs. However, the molecular mechanism of the dimerization of ErbB2 remains elusive. In the present work, we report the homodimer architecture of the ErbB2 extracellular domain (ECD) which is unique compared with other dimer-models of ErbBs. The structure of the ErbB2 ECD homodimer represents a "back to head" interaction, in which a protruding β-hairpin arm in domain II of one ErbB2 protomer is inserted into a C-shaped pocket created by domains I-III of the adjacent ErbB2 protomer. This dimerized architecture and its impact on the phosphorylation of ErbB2 intracellular domain were further verified by a mutagenesis study. We also elucidated the different impacts of two clinically administered therapeutic antibodies, trastuzumab and pertuzumab, on ErbB2 dimerization. This information not only provides an understanding of the molecular mechanism of ErbBs dimerization but also elucidates ErbB2-targeted therapy at the molecular level. In our experiment, we use both of antibody H chain and antibody L chain, which are from 3WLW(Molecular Architecture Of The Erbb2 Extracellular Domain Homodimer). And we use the (GGGGS)3 linker to connect them.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal BglII site found at 24
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


MIT_MAHE 2020

Summary

HER2 is a membrane tyrosine kinase and an oncogene. Studies have shown it to be overexpressed and gene amplified in about 20% of the breast cancers. On activation it provides the cell with potent proliferative and anti-apoptosis signals. It is one of the major driver of tumor development and progression for a subset of breast cancer. This part contains Anti-HER2 single chain variable fragment.

NUM_China 2021

A scFv derevied from Hercetin

This parts codes a scFv derevied from the famous antibody trastuzumab,which sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is given by slow injection into a vein and injection just under the skin.

Trastuzumab was approved for medical use in the United States in September 1998, and in the European Union in August 2000.It is on the World Health Organization's List of Essential Medicines.A biosimilar was approved in the European Union in November 2017, and in the United States in December 2018.

  • Figure 1: Trastuzumab Fab region (cyan) binding HER2/neu (gold) available in PDB.


References

1. Gutierrez, C., & Schiff, R. (2011). HER2: biology, detection, and clinical implications. Archives of pathology & laboratory medicine, 135(1), 55–62. https://doi.org/10.1043/2010-0454-RAR.1